OPKO Health
OPK Small CapHealthcare · Diagnostics & Research
Updated: Jul 6, 2026, 22:20 UTC
Price Chart
Key Metrics
Valuation Analysis
About the Company
OPKO Health, Inc. operates as a healthcare company, in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company operates in two segments, Pharmaceutical and Diagnostics. The Pharmaceutical segment develops MDX2001, a tetra-specific antibody targeting several types of solid tumors in Phase 1 clinical trials; MDX2003, a tetra-specific antibody targeting two antigens for hematological tumors in Phase 1 clinical trials; and MDX2004, a trispecific immune modulator to rebuild and sustain the patient's own immune system. This segment also engages in the development of Epstein Barr Virus vaccine; Rayaldee, a patented extended-release product for oral administration containing 30 mcg of a prohormone; OPK-88006 oral and injectable product to regulate blood glucose a
OPKO Health Stock at a Glance
OPKO Health (OPK) is currently trading at $1.50 with a market capitalization of $1.1B. The 52-week range spans from $0.98 to $1.61; the current price is 6.8% below the yearly high. Year-over-year revenue growth stands at -17.2%.
💰 Dividend
OPKO Health currently does not pay a dividend. The company typically reinvests its earnings into growth initiatives and product development.
📊 Analyst Rating
4 analysts rate OPKO Health (OPK) on consensus: Buy. The average price target is $4.38, implying +191.67% from the current price. Analyst price targets range from $3.00 to $8.50.
OPKO Health: The Investment Case in Detail
OPKO Health (OPK) operates in the Healthcare — specifically Diagnostics & Research — and is headquartered in United States. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.
The Bull Case
Wall Street consensus sits at Buy with an average price target implying roughly 191.67% upside from current levels — analyst sentiment is firmly constructive.
The Bear Case
Revenue is contracting at -17.2% year-over-year — until that trend reverses, valuation is exposed to further downgrades. Net margins remain negative, meaning every euro of revenue is still producing losses — the path to profitability is the central question for shareholders.
Valuation in Context
At a PEG of 93.65, investors are paying more than three times the growth rate for each unit of earnings — that pricing assumes growth not only continues but accelerates from here.
What to Watch Next
- The analyst consensus price target implies 191.67% upside — if the next two quarters confirm the underlying thesis, target hikes typically follow.
Investment Thesis: Strengths & Weaknesses
- Analyst consensus: Buy
- Solid balance sheet with low debt (D/E 32.95)
- –Revenue shrinking (-17.2% YoY)
- –Currently unprofitable
- –Negative free cash flow
Technical Snapshot
The price is in a transition zone relative to the moving averages — no clear signal.
Risk Profile
The data points to market-like volatility, elevated short interest (7.74%).
Trading Data
Related Stocks in the Same Sector
OPKO Health (OPK) 2026: 1,10 USD US Pharmaceutical-and-Diagnostics Holding with Phillip Frost Founder Anchor, BioReference Laboratories Divestiture, Rayaldee Renal-Bone Franchise and Pfizer Somatrogon Royalty
The Real Story
OPKO Health Inc. (NASDAQ: OPK) is a Miami, Florida-headquartered diversified-healthcare company founded by Phillip Frost (former Teva-Pharmaceutical-Industries chairman and serial-biotech-investor). Two segments: Pharmaceutical (Rayaldee renal-bone-mineral, RAYALDEE oral-calcifediol for secondary-hyperparathyroidism in CKD-stage-3-and-4; Modeling-Insights and Eaton drug-discovery-platforms; ModeRNA-platform partnerships) and Diagnostics (BioReference Laboratories clinical-lab-services, in restructuring-and-divestiture process). Pfizer-licensed somatrogon (Ngenla long-acting growth-hormone) royalty stream.
Strategic-pivot: BioReference Laboratories sale-process announced 2024 with multiple-bidder engagement; pharmaceutical-segment-focus on Rayaldee and pipeline-development.
What Smart Money Thinks
OPKO Health has founder-aligned base. Phillip Frost via Frost Gamma Investments holds approximately 30+ percent — dominant founder-anchor since founding. Vanguard at approximately 5,8 percent, BlackRock at approximately 4,2 percent represent passive flows. Frost is structurally-aligned with long-duration value-realization. Short-interest sits at approximately 8 percent of float as of May 2026.
Explore the BMI Smart-Money Tracker →
📈 The 3 Real Bull Points
BioReference Laboratories sale-process with multiple-bidder engagement (Quest Diagnostics, Labcorp, Roper Technologies named as potential buyers per industry press) could generate 300-600 million USD proceeds for OPKO. Net cash proceeds equate to approximately 0,40-0,80 USD per share — substantial relative to current 1,10 USD share-price.
OPKO receives royalty stream from Pfizer Ngenla (somatrogon) which has been FDA-approved-and-EU-approved long-acting growth-hormone for pediatric-growth-hormone-deficiency. Royalty-stream supports approximately 30-50 million USD annual recurring revenue and growing as Ngenla launches scale.
Phillip Frost's 30+ percent ownership through Frost Gamma plus 30-year serial-biotech-investor track-record (founder of Teva, multiple-other-biotech-successes) provides structural capital-allocation discipline. Frost is structurally-aligned with long-duration value-realization.
📉 The 3 Real Bear Points
OPKO continues to operate near-cash-flow break-even with periodic capital-raise requirements. At 1,10 USD share-price, additional equity-issuance creates significant dilution risk.
Rayaldee oral-calcifediol commercial-launch has historically underperformed initial expectations. Continued under-performance plus competitive pressure from cinacalcet-and-other-treatments could compress pharma-segment value.
BioReference Laboratories sale-process pricing-and-timing remains uncertain. Lower-than-expected sale price or delayed-execution could compress value-realization channel.
Valuation in Context
OPKO at 1,10 USD per share with approximately 755 million shares outstanding has a market capitalization of approximately 831 million USD. With minimal net-cash, enterprise value approximately equal to market-cap. TTM revenue approximately 700 million USD (primarily BioReference Laboratories).
Sum-of-parts: BioReference Laboratories sale 0,40-0,80 USD per share; Pharmaceutical segment (Rayaldee plus pipeline plus royalty) 0,30-0,70 USD per share; cash and other 0,20-0,40 USD per share. Fair-value range 0,90-1,90 USD per share. Bear-case 0,60-0,80 USD. Bull-case (BioReference sale at premium plus pipeline progression) 2,20-2,80 USD over 18-24 months.
🗓️ Next 3 Catalyst Dates
-
2026 Q3:
Q2 2026 earnings (early August 2026). Watch-items: BioReference Laboratories sale-process update, Rayaldee commercial trajectory, Ngenla royalty stream.
-
2026 H2:
BioReference Laboratories sale-process resolution (expected H2 2026 per management commentary).
-
2027 Q1:
Fiscal-2026 full-year results plus fiscal-2027 guidance. BioReference sale plus pharma-segment focus would unlock 1,80-2,40 USD range.
💬 Daniel's Take
OPKO Health is a deep-value sum-of-parts US pharma-and-diagnostics holding with Phillip Frost founder-anchor, BioReference Laboratories divestiture catalyst, Pfizer Ngenla royalty stream, and Rayaldee renal-bone-mineral franchise. Position-sizing: 0,3–0,8 percent in deep-value-event-driven sleeve.
Sources (3)
Disclaimer: This article is not investment advice. Investing in stocks carries risks, including total loss.
More Healthcare stocks
Top peers in the same sector — ranked by market cap.
Where can I buy OPKO Health?
Compare top-rated brokers — low fees, trusted providers, fully regulated.
📊 Prefer a fund over a single stock? Compare ETFs:
Live Market Data
Real-time chart, financials, earnings, analysts, insider trades, events & news